2nd Quarter - Report

ROCK & ASSOCIATES for US COMPOUNDING

Firm
Client
Income
$11,250
Expenses
—

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation yet.

LobbyistCovered position, as disclosed
JAMES W ROCK —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Pharmacy PHA

Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation yet.

LobbyistCovered position, as disclosed
JAMES W ROCK —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Budget/Appropriations BUD

Appropriations to fund the FDA implementation of compounding pharmacy regulations. H.R. 4800 and S.2437.

LobbyistCovered position, as disclosed
JAMES W ROCK —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 4800 (113th), S. 2437 (113th)

Law Enforcement/Crime/Criminal Justice LAW

Proposals to amend the Controlled Substances Act to clarify the definition of "dispense" to include the delivery of a controlled substance by a practitioner acting in the usual course of professional practice. No specific legislation yet.

LobbyistCovered position, as disclosed
JAMES W ROCK —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.